| Indoleamine 2, 3-dioxygenase (IDO) inhibitors and cancer immunotherapy Y Fujiwara, S Kato, MK Nesline, JM Conroy, P DePietro, S Pabla, ... Cancer treatment reviews 110, 102461, 2022 | 153 | 2022 |
| Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden C Morrison, S Pabla, JM Conroy, MK Nesline, ST Glenn, D Dressman, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 151 | 2018 |
| Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project DM Vega, LM Yee, LM McShane, PM Williams, L Chen, T Vilimas, ... Annals of Oncology 32 (12), 1626-1636, 2021 | 121 | 2021 |
| Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors JM Conroy, S Pabla, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 96 | 2019 |
| Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients S Pabla, JM Conroy, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-13, 2019 | 92 | 2019 |
| Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors JM Conroy, S Pabla, ST Glenn, B Burgher, M Nesline, ... The Journal of Molecular Diagnostics 20 (1), 95-109, 2018 | 82 | 2018 |
| Visceral obesity promotes lung cancer progression—toward resolution of the obesity paradox in lung cancer J Barbi, SK Patnaik, S Pabla, R Zollo, RJ Smith Jr, SN Sass, A Srinivasan, ... Journal of Thoracic Oncology 16 (8), 1333-1348, 2021 | 51 | 2021 |
| A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors JM Conroy, S Pabla, ST Glenn, RJ Seager, E Van Roey, S Gao, ... PLoS One 16 (12), e0260089, 2021 | 38 | 2021 |
| Body mass index influences the salutary effects of metformin on survival after lobectomy for stage I NSCLC S Yendamuri, J Barbi, S Pabla, C Petrucci, A Punnanitinont, M Nesline, ... Journal of Thoracic Oncology 14 (12), 2181-2187, 2019 | 32 | 2019 |
| Identification of targets for prostate cancer immunotherapy A Papanicolau‐Sengos, Y Yang, S Pabla, FL Lenzo, S Kato, R Kurzrock, ... The Prostate 79 (5), 498-505, 2019 | 30 | 2019 |
| Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response S Pabla, RJ Seager, E Van Roey, S Gao, C Hoefer, MK Nesline, ... Biomarker Research 9 (1), 56, 2021 | 28 | 2021 |
| Cytokeratin-8 in anaplastic thyroid carcinoma: More than a simple structural cytoskeletal protein D Guo, Q Xu, S Pabla, J Koomen, P Biddinger, A Sharma, S Pabla, ... International journal of molecular sciences 19 (2), 577, 2018 | 25 | 2018 |
| Validation of melanoma immune profile (MIP), a prognostic immune gene prediction score for stage II–III melanoma RD Gartrell, DK Marks, EM Rizk, M Bogardus, CL Gérard, LW Barker, Y Fu, ... Clinical Cancer Research 25 (8), 2494-2502, 2019 | 23 | 2019 |
| PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab S George, A Papanicolau-Sengos, FL Lenzo, JM Conroy, M Nesline, ... Oncoimmunology 7 (12), e1460298, 2018 | 22 | 2018 |
| Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing GK Dy, MK Nesline, A Papanicolau-Sengos, P DePietro, CM LeVea, ... BMC Medical Informatics and Decision Making 19, 1-10, 2019 | 21 | 2019 |
| Immune profiling and immunotherapeutic targets in pancreatic cancer FL Lenzo, S Kato, S Pabla, P DePietro, MK Nesline, JM Conroy, ... Annals of Translational Medicine 9 (2), 2021 | 20 | 2021 |
| Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients T Zhang, S Pabla, FL Lenzo, JM Conroy, MK Nesline, ST Glenn, ... Oncoimmunology 9 (1), 1773200, 2020 | 19 | 2020 |
| Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay S Pabla, J Andreas, FL Lenzo, B Burgher, J Hagen, V Giamo, MK Nesline, ... Oncotarget 10 (50), 5181, 2019 | 17 | 2019 |
| Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy P Czajka-Francuz, MJ Prendes, A Mankan, A Quintana, S Pabla, ... Frontiers in Oncology 13, 1200646, 2023 | 16 | 2023 |
| LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics JJ Adashek, S Kato, D Nishizaki, H Miyashita, P De, S Lee, S Pabla, ... Cancer Medicine 12 (12), 13155-13166, 2023 | 15 | 2023 |
